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Background: Heterologous prime-boost vaccination with chimpanzee adenovirus 63 
(ChAd63) and modified vaccinia virus Ankara (MVA) encoding multiple epitope string 
thrombospondin-related adhesion protein (ME-TRAP) has shown acceptable safety 
and promising immunogenicity in African adult and pediatric populations. If licensed, 
this vaccine could be given to infants receiving routine childhood immunizations. We 
therefore evaluated responses to ChAd63 MVA ME-TRAP when co-administered with 
routine Expanded Program on Immunization (EPI) vaccines.
Methods: We enrolled 65 Gambian infants and neonates, aged 16, 8, or 1 week at first 
vaccination and randomized them to receive either ME-TRAP and EPI vaccines or EPI 
vaccines only. Safety was assessed by the description of vaccine-related adverse events 
(AEs). Immunogenicity was evaluated using IFNγ enzyme-linked immunospot, whole-
blood flow cytometry, and anti-TRAP IgG ELISA. Serology was performed to confirm all 
infants achieved protective titers to EPI vaccines.
results: The vaccines were well tolerated in all age groups with no vaccine-related 
serious AEs. High-level TRAP-specific IgG and T cell responses were generated after 
boosting with MVA. CD8+ T cell responses, previously found to correlate with protec-
tion, were induced in all groups. Antibody responses to EPI vaccines were not altered 
significantly.
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Conclusion: Malaria vectored prime-boost vaccines co-administered with routine child-
hood immunizations were well tolerated. Potent humoral and cellular immunity induced 
by ChAd63 MVA ME-TRAP did not reduce the immunogenicity of co-administered EPI 
vaccines, supporting further evaluation of this regimen in infant populations.
Clinical Trial registration: The clinical trial was registered on http://Clinicaltrials.gov 
(NCT02083887) and the Pan-African Clinical Trials Registry (PACTR201402000749217).
Keywords: vaccines, clinical trials, malaria, cellular immune response, cytokines
inTrODUCTiOn
Recent estimates from the World Health Organization (WHO) 
show that many African countries are adopting preventive 
measures toward malaria elimination (1). However, achieving 
this goal would need new interventions to complement current 
control strategies. To curtail the threat posed by emerging resist-
ance to artemisinin-based chemotherapy and insecticide-treated 
bed nets, efforts have intensified to develop potent vaccines as a 
complementary tool (2, 3).
The most clinically advanced malaria vaccine to date, RTS,S, 
has limited efficacy coupled with some safety concerns and 
practical deployment challenges for its four dose regimen in 
target age groups at high risk of malaria (4). Novel approaches 
to generate immunity to malaria employing viral vector vaccines 
were initially limited due to the use of homologous prime-boost 
approaches that induced relatively poor T cell responses (5, 6). 
These have been improved by the development of a novel heter-
ologous approach, which elicits potent and durable cell-mediated 
immunity (7).
Since 2007, we have extensively evaluated heterologous prime-
boost vaccination with chimpanzee adenovirus 63 (ChAd63) 
and modified vaccinia virus Ankara (MVA) expressing the 
Plasmodium falciparum pre-erythrocytic antigen ME-TRAP, a 
multiple epitope string (ME) fused to thrombospondin-related 
adhesion protein (TRAP) among malaria-naïve adults in Europe 
and malaria-exposed adults, children, and infants in Africa 
(8–11). High-level efficacy was observed in Kenyan adults (66%) 
over 8 weeks of follow-up (12). Across four de-escalating pediat-
ric age groups in Burkina Faso and The Gambia, these vaccines 
had acceptable safety profiles and induced primarily CD8+ T cells 
and potent humoral immunity (13, 14).
Due to the very high malaria burden among young infants 
in sub-Saharan Africa, a malaria vaccine should be given in 
early infancy to provide effective protection. During this period, 
routine vaccines are administered to infants according to the 
WHO Expanded Program on Immunization (EPI) schedule. 
Incorporating a new malaria vaccine within an existing EPI 
schedule would facilitate acceptance and uptake by parents and 
reduce logistical costs. However, coadministration with EPI 
vaccines can reduce immunogenicity of new candidate vaccines 
(15); hence, it is crucial to evaluate early the immune responses 
of co-administered vaccines. Such evaluation could also guide the 
selection of optimal vaccination schedules and appropriate infant 
age groups for large efficacy trials (16). Coadministration of 
RTS,S with diphtheria, tetanus, and pertussis (DTP)-containing 
vaccines in a late phase trial may have contributed to the low 
immune responses observed among infants aged 6–12 weeks (17). 
Similarly, coadministration of a candidate tuberculosis vaccine, 
MVA85A, with EPI vaccines resulted in a drop in tuberculosis-
specific immunogenicity (15). These findings underscore the 
importance of appropriate timing of immunizations, both to 
inform the design of efficacy trials involving T cell-inducing vac-
cines and also to prioritize identification of optimal schedules for 
integration within the EPI program (16).
In this study, we investigated the safety and immunogenicity 
of ChAd63 MVA ME-TRAP when co-administered with EPI 
vaccines among Gambian infants aged 16, 8, and 1 week at first 
immunization.
MaTErialS anD METHODS
Objectives
The primary objective was to evaluate the safety and reactogenic-
ity of ChAd63 ME-TRAP and MVA ME-TRAP prime-boost 
immunization when co-administered with EPI vaccines in 
healthy Gambians at ages of 1 and 8, 8 and 16, or 16 and 24 weeks, 
respectively. Secondary objectives were to evaluate both the cel-
lular and humoral immunogenicity of ChAd63 MVA ME-TRAP 
and the antibody responses to EPI vaccines when given alone to 
unvaccinated controls or when co-administered with the candi-
date vaccines within the standard Gambian EPI schedule.
Study Setting
The trial was undertaken from May 2014 to November 2015 at the 
Sukuta field site of Medical Research Council Unit The Gambia 
(MRCG). Sukuta is a peri-urban Gambian settlement located 
about 25 km south of the capital, Banjul. Malaria transmission is 
highly seasonal in this setting, occurring almost exclusively from 
July to January, with a peak in November (18). The predominant 
malaria vector is Anopheles gambiae.
The MRCG has a 42-bed facility for in-patient care. This is 
supported by laboratory and radiology diagnostic facilities. 
Children including neonates presenting with fever (>37.5°C) 
or hypothermia (<35.5°C) lasting more than 24 h in addition to 
danger signs such as convulsion, refusal of feeds, and abnormal 
cry would undergo full septic work-up. These include compre-
hensive clinical evaluation to identify the source of infection. 
To establish the definitive diagnosis, investigations such as full 
blood count, blood culture and CSF analysis are done. Antibiotic 
management is shaped by the result of these tests. Supportive 
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management including fluid management is provided based on 
the clinical needs of the neonates.
Participants
Sensitization meetings were held with the local community to 
identify potential participants for the 16- and 8-week cohorts. 
Prior to enrollment, mothers gave written informed consent 
after the trial information had been explained clearly. For the 
1-week-old group, pregnant women attending antenatal care at 
the government health center located within the field site were 
sensitized from 30 to 32 weeks of gestation. The trial team attended 
the delivery of consenting pregnant women and conducted an 
eligibility assessment and screening tests on the newborn infants.
Exclusion criteria included any evidence of acute or chronic ill-
ness or of hematological, renal or hepatic pathology, birth weight 
less than 2.5 kg, significant antenatal, perinatal or early postnatal 
complications, weight for age z-scores below 2 SDs of normal 
for age, hemoglobin less than 10 g/dl at >4 weeks of age or less 
than 13.0 g/dl at <4 weeks of age, white cell count <5.0 × 109/l, 
positive malaria antigen test, positive maternal HIV serology 
test, clinically significant serum biochemistry results, prior 
receipt of an investigational malaria vaccine, recent or planned 
use of any investigational drug, vaccine, immunoglobulin or any 
blood product, use of immunosuppressant drugs, confirmed or 
suspected immunodeficiency, history of surgical splenectomy, 
and concurrent participation in another clinical trial. The infants 
must have received primary EPI vaccines according to defined 
schedules.
Study Design
The trial comprised three groups enrolled in an age de-escalation 
pattern (Figure  1). The first and second groups had 5 infants 
randomized to receive only EPI vaccines while 10 neonates were 
assigned to EPI vaccines only (control) arm in the third group 
because considerable rates of concurrent illnesses were antici-
pated in the neonatal age group.
The candidate vaccines were administered intramuscularly in 
the three age groups in the left antero-lateral thigh, while the EPI 
vaccines were administered on the right antero-lateral thigh to 
ensure objective comparison of reactogenicity and solicited AEs 
across the study arms. All infants randomized to the vaccine arm 
received ChAd63 ME-TRAP (5 ×  1010 vp) at 1, 8, or 16 weeks 
of age accordingly, followed 8  weeks later by MVA ME-TRAP 
(1 × 108 pfu). All infants were given EPI vaccination according to 
the schedule implemented in the Gambia as follow: BCG and first 
dose of oral polio vaccine (OPV) and hepatitis B vaccine within 
2 weeks of birth, doses 2, 3, and 4 of OPV, and 3 dose primary 
series of 13-valent pneumococcal conjugate, rotavirus (Rotateq), 
and DTP Haemophilus influenza type B (Hib), Hepatitis B pen-
tavalent vaccine at 8, 12, and 16 weeks, followed by measles and 
yellow fever vaccine at 36 weeks of age (Table S1 in Supplementary 
Material).
randomization and Blinding
An independent statistician at the Centre for Statistics in 
Medicine, University of Oxford, performed a block randomiza-
tion of eligible infants for each age group. Sealed envelopes labeled 
with a unique code containing the treatment allocated to each 
eligible infant were provided according to the randomization list. 
This guaranteed treatment concealment until enrollment as the 
envelopes were opened only after the study infants were enrolled. 
However, the clinical investigators and mothers of study infants 
were not blinded to vaccination regimen but the laboratory staff 
who conducted the EPI antibody testing were blinded to the study 
arms.
Sample Size
As this was a Phase Ib trial, the sample size was shaped by the 
need to balance the number required for evaluation of safety 
and immunogenicity of an investigational vaccine with the risk 
of exposing a large group of study participants to an unlicensed 
vaccine. Thus, the sample size was not powered to detect differ-
ences between the study arms.
interventions
Details about the study vaccines have been described elsewhere 
(8–10). Briefly, ChAd63 ME-TRAP and MVA ME-TRAP were 
respectively manufactured by Clinical Biomanufacturing Facility, 
University of Oxford, UK, and Impfstoffwerke Dessau-Tornau, 
Germany, under Good Manufacturing Practice conditions.
Outcomes
The primary endpoint was safety measured as (i) occurrence of 
solicited symptoms during a 3-day follow-up period after each 
immunization; (ii) occurrence of unsolicited symptoms during 
a 30-day follow-up after each vaccination; (iii) occurrence of 
abnormal laboratory results during study period; and (iv) occur-
rence of serious AEs throughout the study period.
assessment of Primary Endpoints (Safety 
and reactogenicity)
After each vaccination, all study infants and neonates were 
directly observed in the trial clinic for 1 h and followed up for 
occurrence of solicited symptoms for three consecutive days. 
The study participants were further assessed for unsolicited 
symptoms for 30 days after each study vaccination. Laboratory 
abnormalities and SAEs were assessed for the entire study period 
(Table 4). Trained field assistants visited the infants at home daily 
for the following 3  days after each vaccination to administer a 
standardized reactogenicity card to the mothers, which included 
history of fever, vomiting, diarrhea, reduced oral intake, and 
reduced activities. The field assistants also examined the infants 
for expected local AEs (swelling, tenderness, limitation of arm 
movement, redness and desquamation at the site of injection) and 
fever. Pain at the injection site was graded on a scale of 0–3 where 
0 = no pain, 1 = painful to touch, 2 = pain when arm is touched, 
and 3 = severe pain at rest.
Further safety assessments were subsequently performed on 
all study infants on days 7, 21, 63, 112, 168, 224, and 252 after 
enrollment. Clinical evaluations consisted of measurement of 
vital signs and assessment for local injection site and general 
solicited symptoms and signs. Local solicited symptoms and 
signs included pain, swelling, redness at injection site while 
Screened (n=24) 
4 ineligible 
Consent withdrawn (n=3) 
Screen failure (n=1) 
16 week group  
Fatal SAE 
(n=1) 
Lost to follow-
up (n=1) 
Vaccine (n=15) Control (n=5) 
Completed 
(n=14) 
Completed 
(n=4) 
Completed 
(n=14) 
Completed 
(n=4) 
Completed 
(n=13) 
Completed 
(n=4) 
Completed 
(n=13) 
Completed 
(n=4) 
Enrolled (n=20) 
Lost to 
follow-up  
(n=1) 
Screened (n=22) 
8 week group  
Vaccine (n=15) Control (n=5) 
Completed 
(n=15) 
Completed 
(n=5) 
Completed 
(n=15) 
Completed 
(n=5) 
Completed 
(n=15) 
Completed 
(n=5) 
Completed 
(n=15) 
Completed 
(n=5) 
Enrolled (n=20) 
1 ineligible 
Consent withdrawn (n=1) 
Screened at birth (n=26) 
1 week group  
Vaccine (n=15) Control (n=10) 
Completed 
(n=15) 
Completed 
(n=10) 
Completed 
(n=15) 
Completed 
(n=10) 
Completed 
(n=15) 
Completed 
(n=10) 
Completed 
(n=15) 
Completed 
(n=10) 
Enrolled (n=25) 
D112 follow up 
D168 follow up 
D63 follow up 
ChAd63 prime (D0) 
MVA boost (D56) 
FiGUrE 1 | Flow of study design and volunteer enrollment. Seventy-two infants and neonates were screened for eligibility across the three age groups and 65 
eligible infants were enrolled, randomized, vaccinated according to randomization list and followed up for 252 days. Of 24 infants screened in the 16-week-old 
group, mothers of 3 infants withdrew consent before enrollment while 1 infant was excluded due to markedly raised alanine transaminase. Among those randomized 
to the vaccine arm, one infant had fatal SAE that was non-related to the study vaccines and another was lost to follow-up due to relocation of mother, while only one 
infant did not complete the follow-up in the control arm. Twenty-two infants were screened for the 8-week-old cohort and all were eligible. Only the first 20 were 
randomized into 15 vaccine group and 5 controls. Similarly, 26 mother-newborn pairs were screened for the 1-week-old group. A mother withdrew consent before 
enrollment and the remaining 25 neonates were randomized into 15 vaccinees and 10 controls. All study infants in the 8- and 1-week-old groups completed the 
study follow-up. SAE, serious adverse event.
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systemic solicited symptoms and signs included fever (axillary 
temperature of >38.0°C), reduced oral intake, reduced activity, 
and vomiting. Any other symptoms or signs were considered 
unsolicited and were recorded during the 30  days after each 
vaccination while SAEs were monitored throughout the study 
period. Blood samples were collected at screening visit and study 
days 21, 63, 112, and 168 to determine complete blood count, 
alanine transaminase (ALT), and serum creatinine.
Adverse events were graded by intensity and judged for relat-
edness to study vaccines. Mild AEs were easily tolerated, causing 
minimal discomfort and not interfering with daily activities. 
Moderate AEs were sufficiently discomforting to interfere with 
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normal activities. Severe AEs prevented normal daily activities. 
Swelling, redness and fever had specific definitions not based 
on interference with daily activities. Injection site swelling and 
redness were graded based on their widest dimension: mild, 
0–20 mm; moderate, 20–50 mm; and severe, >50 mm. Fever was 
classified as severe if the axillary temperature was ≥40.0°C. For 
laboratory tests, toxicity grading was adapted to normal reference 
ranges determined for the local infant population (19).
Blood Processing
Blood samples were collected using the heparinized Vacutainer® 
system (Becton Dickinson) and stored at room temperature 
(RT) prior to processing, which was completed within 6  h of 
venipuncture. PBMC were separated by density centrifugation 
from whole blood and re-suspended in RPMI (Sigma) contain-
ing 10% heat-inactivated, batch tested, sterile-filtered fetal calf 
serum (FCS) previously screened for low reactivity (Labtech 
International), 1% l-glutamine, and 1% penicillin/streptomycin. 
Cell counts were performed using trypan blue (Sigma) staining 
and a microscope according to an established laboratory SOP.
Ex Vivo Enzyme-linked immunospot 
(EliSpot) assays
Ex vivo (18-h stimulation) ELISpot assays were performed using 
Multiscreen IP ELISpot plates (Millipore), human IFNγ SA-ALP 
antibody kits (Mabtech), and BCIP NBT-plus chromogenic 
substrate (Moss Inc). Cells were cultured in RPMI containing 
10% heat-inactivated, sterile-filtered FCS, supplemented with 
1% l-glutamine, and 1% penicillin/streptomycin. Antigens were 
tested in duplicate with 250,000 PBMC added to each well of the 
ELISpot plate. TRAP peptides were 20 amino acids in length, 
overlapping by 10 amino acids (NeoBioLab), assayed in 6 pools 
of 7–10 peptides at a final concentration of 10 µg/ml. Responses 
were averaged across duplicates and responses in unstimulated 
(negative control) wells were subtracted. Responses to the T9/96 
strain of the TRAP antigen were evaluated by summing responses 
to individual pools. Responses to TRAP from 3D7 strain were 
tested using a single pool of peptides covering the entire sequence 
of the TRAP antigen. Staphylococcal Enterotoxin B (0.02 µg/ml) 
and phytohemmagglutinin-L (10  µg/ml) were used as positive 
control. Plates were counted using an AID automated ELISpot 
counter (AID Diagnostika GmbH, algorithm C) and using identi-
cal settings for all plates, and counts were adjusted only to remove 
artifacts. Responses to the negative control were always less than 
20 spot-forming cells (SFC) per well.
Pools were considered positive if the response was both greater 
than the background response plus five SFC and two times higher 
than the negative control for that assay. The lower limit of detec-
tion (LLD) for the assay was 4 SFC/million PBMC for individual 
pairs of wells and 28 SFC/million PBMC for the response to 
ME-TRAP.
Whole Blood Stimulation for intracellular 
Cytokine Staining (iCS) analysis
Thrombospondin-related adhesion protein-specific CD4+ and 
CD8+ T  cell responses were further characterized in blood 
samples taken from vaccinees, 21 days post-priming with ChAd63 
ME-TRAP and 7 days post-boosting with MVA ME-TRAP (at 
day 63) by intracellular staining. Secretion of IFNγ, IL-2, and 
TNFα by T  cells was measured following in  vitro recall with a 
single pool of peptides spanning the entire sequence of TRAP 
protein from T9/96 P. falciparum strain.
The whole blood ICS protocol was adapted from Hanekom 
et  al. (20) and optimized to include dead cell identification 
through non-fixation of samples ahead of red cell lysis, thus ena-
bling a cell viability readout, in addition to the exclusion of dead 
or dying cells, which often auto-fluoresce and/or non-specifically 
bind the antibodies used in flow cytometry. 350 µl of blood were 
distributed in 2  ml screw-cap tubes (Sarstedt) and stimulated 
in the presence of 0.5  µg/ml of anti-CD49d and anti-CD28 
monoclonal antibodies (eBioscience) and a final concentration 
of 2 µg/ml of a pool of 56 20mers, overlapping by 10 amino acids, 
covering the full sequence of the TRAP antigen from the T9/96 
P. falciparum strain (Neopeptide). Staphylococcal Enterotoxin B 
(Sigma) at 2 µg/ml or an equivalent volume of RPMI medium 
supplemented with 10% heat-inactivated FCS, 1% penicillin/
streptomycin, and 1% l-glutamine were used as positive and 
negative controls, respectively. Tubes were incubated at 37°C in 
5% CO2 for 2–4 h, prior to the addition of 1 µg/ml Brefeldin A 
(eBioscience) and further incubation at 37°C for 16 h. At the end 
of the culture, samples were then incubated with 2 mM EDTA 
(Gibco) for 15  min to remove adherent cells, then treated for 
2 × 10 min with Red Cell Lysis Buffer (Qiagen). Cells were then 
stained at RT for 20 min in the dark with Live/Dead fixable Aqua 
amine reactive dye (Life Technologies) for live cell identification 
and fixed with 1% paraformaldehyde (Sigma) in phosphate-
buffered saline (PBS) for 5 min. Cells were subsequently frozen in 
0.5 ml FCS containing 10% DMSO (Sigma) and stored at −80°C 
until further use for batched analysis.
Multiparameter Flow Cytometry analysis
The T cell cytokine response to the pooled peptides was assessed 
on stimulated whole blood using an 8-color antibody panel. Cells 
were thawed and stained in batches within 4 months of the date 
they were frozen. Each participant’s day 21 and day 63 samples 
were analyzed on the same day for consistency. After thawing, 
cells were transferred in polystyrene FACS tubes and washed with 
FACS buffer [PBS containing 0.1% bovine serum albumin (BSA) 
and 0.01% sodium azide (both from Sigma)]. Samples were then 
prepared following a staining protocol standardized across all 
trial sites (11, 14). After 20 min of permeabilization in Cytofix/
Cytoperm buffer (BD Biosciences) at RT in the dark, cells were 
washed once in 1× Perm/Wash Buffer (BD Biosciences). Cells 
were then stained at RT for 30 min with a combined surface and 
intracellular cocktail containing CD3 AlexaFluor700 (1/50, clone 
UCHT1), CD4 APC (1/25, clone Leu-3), CD8 APC-eFluor780 
(1/10, clone RPAT8), CD14 eFluor450 (1/50, clone 61D3), CD19 
eFluor450 (1/50, clone SJ25-C1), IFNγ FITC (1/100, clone 4S.B3), 
IL-2 PE (1/50, clone MQ1-17H12), and TNFα PECy7 (1/500, 
clone MAb11) monoclonal antibodies (all from eBioscience). 
Samples were washed in 1× Perm/Wash Buffer and re-suspended 
in 1% paraformaldehyde (Sigma) in PBS for consistency across 
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all trial sites due to logistic issues that can arise at acquisition. 
Samples were then analyzed using a BD LSR Fortessa Cell 
Analyzer (Becton Dickinson). Compensation was calculated 
for each fluorochrome on each acquisition run using OneComp 
beads (eBioscience) for surface and intracellular antibodies and 
ARC beads (Life Technologies) for Aqua reactive dye. An aver-
age of 700,000 total events (IQR: 493,669–851,834 events) was 
collected per sample. Figure S1 in Supplementary Material shows 
the hierarchical gating strategy for this analysis. A minimum of 
55,000 live CD3+ lymphocytes was analyzed for each sample. At 
least 23,000 CD4+ or CD8+ T  cells were analyzed for multiple 
cytokine expression after exclusion of any double positive cells, 
respectively. Any sample with less than 23,000 events in the CD4+ 
or CD8+ gate was excluded. 8 out of 88 samples (corresponding 
to 1 sample for the CD4+ and 7 for the CD8+ T  cell cytokine 
response analysis) with a total cytokine response to the positive 
control lower than 1% cytokine positive CD4+ or CD8+ T cells 
were further excluded from subsequent analysis. Responses were 
calculated after background subtraction, corresponding to the 
response in the medium control for each sample. The LLD of 
the assay, corresponding to 1/minimum number of events in the 
CD4+ or CD8+ gate*100, was 0.0047% of the parent population 
for all three cytokines for both CD4+ and CD8+ T cells. A posi-
tive response was strictly greater than one time the unstimulated 
control of the corresponding sample. Any response failing this 
criterion was considered negative and was replaced by LLD value 
or excluded from analysis when stated otherwise. Bar charts were 
created using absolute frequencies. Pie charts were generated 
using relative frequencies with a threshold of 0.004% of the parent 
population. Data analysis was performed using FlowJo v10.1r1 
(Treestar Inc., USA), Pestle v1.7, and Spice v5.3 (Mario Roederer, 
Vaccine Research Centre, NIAID, NIH, USA).
TraP-Specific Total igG EliSa
Antibody responses were measured by anti-TRAP IgG sandwich 
ELISA. Nunc-Immuno 96 well plates were coated with 0.5 µg/ml 
of TRAP antigen from 3D7 Pf strain in carbonate-bicarbonate 
coating buffer and left overnight at 4°C. Plates were washed 
six times with phosphate-buffered saline-Tween (PBS/T), then 
blocked with 1% BSA in PBS/T for 1 h at RT. Serum was diluted 
in PBS/T containing 0.2% BSA at concentrations of 1:100, 
1:500, or 1:1,000, and added in triplicate. Serum samples from 
the screening visit, days 21, 56, 63, 112, and 168, were analyzed. 
Plates were incubated at RT for 2  h then washed as before. A 
secondary antibody (goat anti-human whole IgG conjugated to 
alkaline phosphatase, Sigma) was added at a dilution of 1:1,000 
in PBS/T 0.2% BSA for 1 h at RT. After a final wash, plates were 
developed by adding 4-nitrophenyl phosphate in diethanolamine 
buffer (Pierce). A positive reference standard (made from pooled 
TRAP-positive serum) was used on each plate to give a standard 
curve. It was added in duplicate at an initial dilution of 1:100 (in 
PBS/T 0.2% BSA) and diluted twofold 10 times, starting with an 
arbitrary value of 20 antibody units. Four blank wells (0 antibody 
units) were also designated. The optical density (OD) values were 
then fitted to a four-parameter standard curve using SOFTmax 
PRO software. An internal control was included on every plate in 
triplicate made up from a 1:800 dilution (in PBS/T 0.2% BSA) of 
the positive standard. OD was read at 405 nm using an ELx800 
microplate reader. Test sera antibody units were calculated from 
their OD values using the parameters estimated from the stand-
ard curve. Previously published data shown for comparison in 
Figure 7B was generated using the same ELISA assay performed 
in the same laboratory by the same technician and is therefore 
comparable to this dataset.
Serology to EPi Vaccines
Serology for responses to EPI vaccines at 24 weeks (8 weeks after 
last primary EPI) was performed at the National Institute for 
Public Health and the Environment (RIVM) in the Netherlands. 
IgG antibodies directed against Bordetella pertussis, diphtheria, 
tetanus, Hib, and 13 Streptococcus pneumoniae serotypes were 
measured in duplicate using fluorescent bead-based multiplex 
immuno assays (Luminex xMAP technology) (21–23). In all 
assays, a reference, controls and blanks were included on each 
plate. All analyses were performed with a Bio-Plex 200 in com-
bination with Bio-Plex manager software (Bio-Rad Laboratories, 
Hercules, CA, USA). For the B. pertussis, diphtheria and tetanus 
(DTaP) multiplex assay, samples were diluted 1:200 and 1:4,000 
in PBS containing 0.1% Tween-20 and 3% BSA. Serum values 
for B. pertussis were assigned in endotoxin units per milliliter 
as the used in-house reference was calibrated against the U.S. 
Reference Pertussis Anti-serum Human lot 3 (CBER/FDA). Hib 
IgG antibodies were determined similar to the DTaP multiplex 
assay, with the exception that sera were diluted 1:100 and 1:400 
in 50% antibody depleted human serum. Values were expressed 
in micrograms per milliliter as the used in-house reference was 
calibrated against lot 1983 (CBER/FDA). Pneumococcal IgG 
antibody concentrations of serotypes included in PCV13 were 
simultaneously measured by diluting the sera 1:1,000 in PBS 
containing 15  µg/ml cell wall polysaccharide Multi (Statens 
Serum Institute, Copenhagen, Denmark) and 5% antibody 
depleted human serum to reduce non-specific reactions. Serum 
values were expressed in µg/ml as the used in-house reference was 
calibrated against lot 89-S serum (CBER/FDA). For Hepatitis B, 
antibodies to the surface antigen were measured using the Abbot 
Architect 2000i chemiluminescent micro-particle immunoassay, 
product # 7C18. Antibody concentration is determined against a 
calibration curve with a concentration of 10.0 mIU/ml or greater 
considered positive.
Statistical Methods
Safety and clinical laboratory data were double-entered on 
OpenClinica® software and analyses were performed using 
STATA Release statistical software version 14.1 (StataCorp LP, 
College Station, TX, USA). For categorical variables, data were 
summarized using absolute numbers and percentages and groups 
were compared with Fisher’s exact test (FET). For continuous 
variables, the median and inter-quartile range or geometric 
mean with 95% confidence interval (CI) were used to summarize 
the data. Intent to treat analysis was used. For immunological 
data, statistical analyses were performed using GraphPad Prism, 
Mac version 6 (GraphPad Software Inc., USA) or Spice v5.3 
(Mario Roederer, Vaccine Research Centre, NIAID, NIH, USA). 
Geometric mean responses are shown for each group, unless 
TaBlE 1 | Baseline demographic and laboratory parameters of study infants.
age group 16-week old 8-week old 1-week old
randomized group Vaccine (n = 15) Control (n = 5) Vaccine (n = 15) Control (n = 5) Vaccine (n = 15) Control (n = 10)
Sex (female) 7 (47.7%) 3 (60.0%) 9 (60.0%) 2 (40.0%) 12 (80.0%) 3 (30.0%)
Median (iQr) Median (iQr) Median (iQr)
Hemoglobin (g/dl) 10.9 (10.1–12) 10.4 (10.3–10.7) 11.6 (10.9–13) 11.5 (10.8–11.8) 19.1 (16.8–20.4) 18.45 (16.5–20.9)
White cell count (×109/l) 8.4 (7.8–9.3) 10.9 (8.7–14.3) 10.4 (8.7–13.6) 7.4 (6.8–11.2) 18 (13–19.8) 14.95 (13.9–17)
Neutrophil count (×109/l) 1.9 (1.2–2.7) 1.4 (0.8–2.3) 3.4 (2.9–5.2) 1.6 (1.4–3.6) 10.8 (6.8–13.3) 5.1 (4.2–9.4)
Lymphocyte count (×109/l) 5.5 (4.4–6.5) 7.7 (6.0–10.4) 5.7 (4.2–8.2) 4.9 (4.4–8.4) 5.4 (3.8–5.3) 7.0 (5.0–10.2)
Platelet count (×109/l) 403 (282–559) 591 (552–667) 295 (250–389) 271 (255–272) 185 (158–233) 136.5 (108–239)
Alanine transaminase (ALT) (μmol/l) 26 (17–32) 24 (24–26) 18 (15–25) 21 (20–33) 21 (16–29) 19.5 (14–25)
Creatinine (U/l) 11 (10–15) 13 (13–14) 21 (18–23) 21 (19–21) 55 (51–57) 53.5 (43–64)
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stated otherwise in the figure legends. Differences in ELISpot 
responses over the time course of follow-up were tested for 
significance using the Friedman matched-pairs non-parametric 
test, while variations in responses between individual time 
points were compared for each infant within each age group 
using the Wilcoxon matched-pairs signed rank test, respectively. 
Infants with missing data at any time point were excluded from 
matched-pairs analyses. Mann–Whitney U test was used to 
compare responses in vaccinees to those of controls within the 
same age group at a specific time point. Differences across groups 
in peak ELISpot responses or in intracellular cytokine responses 
were analyzed using the Kruskal–Wallis test with Dunn’s multiple 
comparison post-test. Similarly, variations between post-prime 
and post-boost responses measured by intracellular staining 
were compared for each cytokine, on CD4+ and CD8+ T  cells 
separately, using Kruskal–Wallis test with Dunn’s correction for 
multiple comparisons. This non-paired analysis was chosen to 
gain some statistical power over a matched-pairs test, as several 
data points were missing from this dataset. Comparisons between 
study groups of the T cell phenotype distribution of peak CD4+ 
and CD8+ T  cell responses was achieved by a non-parametric 
partial permutation test using 10,000 iterations in SPICE (24). 
All statistical tests were two-tailed and a p-value of less than 0.05 
was considered significant.
Ethical Considerations and regulatory 
Study approval
An independent data safety monitoring board (DSMB) was 
appointed before the trial began to provide oversight and to review 
the safety data reports as the trial progressed. An experienced 
local pediatrician served as the local safety monitor (LSM) and, 
along with the DSMB, reviewed safety data for 16- and 8-week-
old infants before commencing vaccination in the 1-week-old 
group. The trial was conducted according to ICH Good Clinical 
Practice guidelines and the Declaration of Helsinki principles; 
and was monitored by an external organization (Appledown 
Clinical Research Ltd., UK). The trial protocol was also approved 
by the Gambia Government/Medical Research Council (MRC) 
Joint Ethics Committee, The Gambia Medicines Board and 
Oxford Tropical Research Ethics Committee (OXTREC Number: 
7-14). This clinical trial was registered with http://clinicaltrials.
gov (NCT02083887) and the Pan African Clinical Trials Registry, 
www.pactr.org (PACTR 201402000749217).
rESUlTS
recruitment
Seventy-two infants and neonates were screened for eligibility 
and 65 eligible infants were enrolled, randomized, vaccinated 
according to randomization list and followed up for 252 days. The 
participant flow chart is shown in Figure 1, while the baseline 
demographic and laboratory parameters are summarized for 
each group in Table 1.
Safety and reactogenicity
Following ChAd63 ME-TRAP coadministration with EPI 
vaccines in the 16-week-old cohort, fever was documented in 
similar numbers of infants (11/15, 73%) compared to the control 
(EPI vaccines only) group (80%, 4/5, p = 0.63 by FET) (Table 2). 
Excessive crying was recorded in 60% (3/5) and 40% (8/15) of the 
controls and vaccinees, respectively (p = 0.60 by FET). Episodes 
of discoloration and swelling at EPI site were similar in frequency 
(2/15 vs. 1/5) (Table 3).
A fatal SAE was recorded in a female study infant 5 days after 
coadministration of ChAd63 ME-TRAP with EPI vaccines. Vital 
signs immediately post-vaccination and during the 3-day post-
vaccination follow-up were within acceptable ranges. Mother 
attended a social event with the child 5 days after receiving the 
vaccines and the child reportedly died while sleeping. Verbal 
autopsy report suggested that the probable cause of death was 
sudden infant death syndrome, and this was considered not likely 
to be related to the study vaccine.
After vaccination with MVA ME-TRAP, as expected, a higher 
proportion of vaccinees had systemic AEs than the controls (fever: 
10/15, 67% vs. 1/5, 20%, p = 0.09; vomiting: 2/15, 13% vs. 0/5, 
0%, p = 0.53 using FET) (Table 2). For both ChAd63 and MVA 
ME-TRAP, the onset of most of the AEs was 24 h after vaccination 
and resolution was within 48 h. The AEs were of mild intensity 
and were considered possibly related to the study vaccines.
In the 8-week-old group, all AEs reported after vaccination 
with EPI vaccines alone or with ChAd63 ME-TRAP were mild 
and resolved within 1  day of onset, with fever being the most 
TaBlE 2 | Systemic solicited adverse events during 3-day follow-up after each study vaccination.
Post-Chad63 multiple epitope string thrombospondin-related 
adhesion protein (ME-TraP)
Post-MVa ME-TraP
age group 16 weeks 8 weeks 1 week 16 weeks 8 weeks 1 weeks
n (%) Vaccine Control Vaccine Control Vaccine Control Vaccine Control Vaccine Control Vaccine Control
Reported fever 1 (6.7) 5 (100.0) 7 (46.7) 5 (100.0) 14 (93.3) 7 (70.0) 2 (13.3) 0 4 (26.7) 2 (40.0) 15 (100.0) 7 (70.0)
Documented fever 11 (73.3) 4 (80.0) 10 (66.7) 1 (20.0) 8 (53.3) 1 (10.0) 10 (66.7) 1 (20.0) 12 (80.0) 2 (40.0) 9 (60.0) 1 (10.0)
Excessive crying 8 (53.3) 3 (60.0) 6 (40.0) 4 (80.0) 10 (66.7) 4 (40.0) 2 (13.3) 0 10 (66.7) 2 (40.0) 9 (60.0) 3 (30.0)
Refusal of feed 1 (6.7) 1 (20.0) 1 (6.7) 0 1 (6.7) 0 0 0 3 (20.0) 0 1 (6.7) 0
Vomiting 1 (6.7) 0 2 (13.3) 2 (40.0) 2 (13.3) 1 (10.0) 0 0 6 (40.0) 0 1 (6.7) 2 (20.0)
Diarrhea 8 (53.3) 1 (20.0) 3 (20.0) 1 (20.0) 5 (33.3) 2 (20.0) 0 0 5 (33.3) 0 3 (20.0) 1 (10.0)
This table shows that following ChAd63 and MVA ME-TRAP administrations, fever, excessive crying, refusal of feed, vomiting, and diarrhea were more frequently observed among 
1- and 8-week-old cohorts than 16-week-old cohort.
TaBlE 3 | Local solicited adverse events during 3-day follow-up after each study vaccination.
Post-Chad63 multiple epitope string thrombospondin-related 
adhesion protein (ME-TraP)
Post-MVa ME-TraP
age group 16 weeks 8 weeks 1 week 16 weeks 8 weeks 1 week
n (%)a Vaccine Control Vaccine Control Vaccine Control Vaccine Control Vaccine Control Vaccine Control
EPI site pain 1 (6.7) 0 10 (66.7) 2 (40.0) 3 (20.0) 4 (40.0) 0 0 2 (13.3) 0 4 (26.7) 5 (50.0)
Limitation of movement 
at EPI site
0 0 0 0 0 0 0 0 0 0 1 (6.7) 0
Study vaccine site pain 0 0 0 0 0 0 1 (6.7) 0 0 0 0 0
EPI site discoloration 2 (13.3) 1 (20.0) 4 (26.7) 0 1 (6.7) 2 (20.0) 0 0 0 0 2 (13.3) 2 (20.0)
Study vaccine site 
discoloration
0 0 0 0 0 0 1 (6.7) 0 1 (6.7) 0 0 0
EPI site swelling 1 (6.7) 1 7 (46.7) 1 (20.0) 0 2 (20.0) 0 0 6 (40.0) 2 (40.0) 1 (6.7) 2 (20.0)
Study vaccine site swelling 0 0 0 0 0 0 1 (6.7) 0 0 0 0 0
aFor 16- and 8-week groups, n = 15 for vaccine arm and n = 5 for control arm, while for 1-week group, n = 15 for vaccine arm and n = 10 for control arm.
This table shows that pain, discoloration, and swelling at EPI injection sites were more frequently reported in participants who received EPI with study vaccines across all age groups.
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frequently reported among those in the vaccine arm (10/15, 67%) 
(Table 2). Similarly, following MVA ME-TRAP vaccination, fever 
was the most commonly reported AE in the vaccine arm (12/15, 
80% vs. 2/5, 40%, p = 0.13 using FET, Table 2). Similarly, exces-
sive crying, refusal of feeds, and vomiting were more frequently 
observed in the control group post-ChAd63 administration, 
while these symptoms were reported more frequently in the 
vaccine recipients post-MVA vaccination. These were of mild 
intensity (Grade 1) and were considered to be possibly related to 
the study vaccines.
More systemic AEs were observed in the neonates who received 
ChAd63 ME-TRAP with EPI vaccines than those who received 
EPI vaccines only (fever: 8/15, 53% vs. 1/10, 10%, p = 0.03 using 
FET, Table 2). Similarly, following MVA ME-TRAP vaccination, 
frequently observed AEs in the vaccine arm included fever (60 
vs. 10%, p = 0.02) and excessive crying (60 vs. 30%, p = 0.12) 
(Table 2). The AEs were mild in intensity and were observed 24 h 
after vaccination and resolved within 48 h. Also, higher propor-
tion of study infants in the control arm had pain at EPI injection 
site (50 vs. 26.7%, p = 0.22), discoloration at EPI injection site (20 
vs. 13.3%, p = 0.53) and swelling at EPI site (20 vs. 6.7%, p = 0.37, 
using FET) (Table 3).
Prominent among unsolicited AEs during 30 days after each 
study vaccination were upper respiratory tract infection in 20% 
of study vaccine recipients among 16-week-old cohort and skin 
sepsis in 1- and 8-week old cohort (13.3 and 73.3%, respectively) 
(Table 4). Owing to mild intensity of these symptoms, the par-
ticipants were clinically investigated to establish the definitive 
diagnoses and exclude possible complications. The participants 
with skin sepsis (impetigo) were subsequently treated with full 
course of antimicrobials on out-patient basis and they made 
remarkable clinical recovery. Low hemoglobin observed in one 
neonate (6.7%) in the vaccine group was investigated and found 
to be due to physiological decline of hemoglobin in early weeks of 
life. This was corrected with hematinics and the participant made 
sustained clinical improvement. These events were considered 
not related to the study vaccines, given that they occurred more 
than 2 weeks post-vaccinations.
A SAE occurred due to hospitalization in a female infant who 
developed severe bronchopneumonia 4  days after vaccination 
with MVA ME-TRAP and EPI vaccines. She was managed with 
intravenous antibiotics and intranasal oxygen. After clinical 
improvement, she was discharged home 5 days after admission. 
This event was considered unlikely to be related to the study 
vaccine.
Except for low hemoglobin reported in two participants (one 
in vaccine group in 1-week-old cohort and another in control 
group of 16-week-old cohort), all hematological and biochemical 
TaBlE 4 | Incidence of unsolicited adverse events during 30 days after study immunizations.
Post-Chad63 multiple epitope string  
thrombospondin-related adhesion protein (ME-TraP)
Post-modified vaccinia virus ankara (MVa) ME-TraP
age group 16 weeks 8 weeks 1 week 16 weeks 8 weeks 1 week
n (%) Vaccine Control Vaccine Control Vaccine Control Vaccine Control Vaccine Control Vaccine Control
Upper respiratory tract infection 3 (20.0) 1 (20.0) 5 (33.3) 0 1 (6.7) 0 0 0 1 (6.7) 0 1 (6.7) 1 (20.0)
Low hemoglobin 0 1 (20.0) 0 0 0 0 0 0 0 0 1 (6.7) 0
Acute conjunctivitis 0 0 0 0 1 (6.7) 0 0 0 0 0 0 0
Pustular scalp sepsis 0 0 0 0 1 (6.7) 1 (20.0) 0 0 0 0 0 0
Skin sepsis 0 0 0 0 2 (13.3) 0 1 (6.7) 0 11 (73.3) 1 (20.0) 0 0
Restlessness 0 0 0 0 1 (6.7) 0 0 0 0 0 0 0
Eye discharge 0 0 0 0 0 0 1 (6.7) 0 0 0 0 0
Moderate bronchiolitis 0 0 0 0 0 0 1 (6.7) 0 0 0 0 0
Tinea capitis 0 0 0 0 0 0 0 0 0 0 1 (6.7) 0
Skin sepsis (impetigo) was frequently reported in 8-week-old cohort (73.3%) following MVA-ME-TRAP and one neonate post-ChAd63 vaccination. Low hemoglobin observed in 
another neonate was due to physiological decline in early life.
FiGUrE 2 | Ex vivo IFNγ enzyme-linked immunospot responses to multiple epitope string thrombospondin-related adhesion protein (ME-TRAP) pre- and 
post-vaccination with ChAd63 and MVA ME-TRAP in Gambian infants. (a–C) Scatter plots show individual responses to ME-TRAP in both vaccinees (in black) 
and controls (in white) of each age group. (a) 16-week-old; (B) 8-week-old; (C) 1-week-old infants. (D) Geometric mean ME-TRAP responses in each age group 
over period of follow-up. LLD, lower limit of detection of the assay. Increases in responses over the time course were analyzed using two-tailed Friedman test. 
Responses between individual time points were compared within each age group using two-tailed Wilcoxon analysis, *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001. Lines and numbers in blue denote geometric mean. Numbers shown in black represent the percentage of responders among the vaccinated 
infants for each time point.
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FiGUrE 3 | Peak enzyme-linked immunospot (ELISpot) responses to 
multiple epitope string thrombospondin-related adhesion protein (ME-TRAP) 
at D63, 7 days post-MVA. (a) Peak responses from vaccinated infants 
expressed per million PBMC. (B) Lymphocyte counts per milliliter of blood at 
D63. (C) ELISpot responses expressed per ml of blood. LLD, lower limit of 
detection of the assay. Peak responses and cell counts were compared 
across groups using Kruskal–Wallis test with Dunn’s multiple comparison 
post-test, *p < 0.05. Lines and numbers indicate geometric mean.
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parameters were within normal ranges throughout the follow-up 
period across the study arms. No participants developed clinical 
malaria during the study.
immunogenicity
T Cell Responses to Vaccination
A significant increase in ME-TRAP-specific IFNγ responses 
from baseline was observed 21 days after priming with ChAd63 
ME-TRAP in all vaccinees as compared to controls, using an 
ex vivo IFNγ enzyme-linked immunospot (ELISpot) assay 
(Figures 2A–C). Vaccination with MVA ME-TRAP boosted the 
magnitude of these responses, which increased significantly from 
post-priming levels in all age group. One week post-MVA, 100% 
responder frequency was observed in all age groups and peak 
geometric mean responses reached 1,436 [with 95% confidence 
interval (95% CI 1,190–2,388), 1,759 (95% CI 1,467–2,515), and 
755 (95% CI 622–1,568) SFC per million PBMC for the 16-, 8-, 
and 1-week-old infants, respectively, as compared with pre-boost 
responses of 154 SFC (95% CI 84–395), 283 SFC (95% CI 209–546), 
and 254 SFC (95% CI 182–590) per million PBMC, p = 0.0012, 
p = 0.0002, p = 0.0043, respectively, two-tailed Wilcoxon test]. 
IFNγ T cell responses were maintained significantly above post-
priming levels up to 112  days following boost vaccination in 
all vaccinated groups (day 168, Figure 2D), while responses in 
controls remained below 100 SFC throughout follow-up. Because 
lymphocyte counts per milliliter of blood can vary with age (14, 
25), we expressed peak responses 1 week post-boost (at day 63) 
as SFC per milliliter of blood by combining lymphocyte counts 
collected at this time point during routine hematology tests 
(Figure 3). Using this unit, highest responses to vaccination with 
ChAd63 MVA ME-TRAP were still observed in the infants aged 
8 weeks at first vaccination (p > 0.99 and p = 0.015 when com-
pared to the 16- and 1-week-old infants, respectively, two-tailed 
Kruskal–Wallis test with Dunn’s correction for multiple tests) 
(Figure  3C), as lymphocyte counts did not vary significantly 
between groups (Figure 3B).
IFNγ ELISpot responses to the TRAP antigen were always 
significantly higher than those to the ME string (Figure S2 in 
Supplementary Material) and were relatively broad (Figure S3 in 
Supplementary Material). Responses to TRAP from heterologous 
3D7 P. falciparum strain were of comparable magnitude as com-
pared to the corresponding responses to TRAP from homologous 
T9/96 vaccine strain throughout follow-up in all age groups 
(Figure  4). In addition, peak responses, 1  week post-MVA, to 
both strains strongly correlated (r = 0.813, p = 0.0012; r = 0.770, 
p = 0.0012; r = 0.986, p < 0.0001, in the 16-, 8-, and 1-week-old 
groups, respectively, Spearman correlation test), showing induc-
tion of highly cross-reactive T cells by vaccination with the T9/96 
strain.
TRAP-Specific T Cell Response Cytokine Profile
In all groups, prime-boost immunization with ChAd63 MVA 
ME-TRAP induced both CD4+ and CD8+ TRAP-specific T cells 
(Figures S4 and S5 in Supplementary Material). IFNγ production 
by both T  cell subsets was detected in all age groups 3  weeks 
post-prime vaccination. Boost immunization with MVA induced 
a marked increase in the magnitude of these responses, although 
it only reached significance for the CD4+ T cell response in the 
oldest and the youngest infants (p = 0.002 and p = 0.01, respec-
tively, Kruskal–Wallis test, Figures S4B–D in Supplementary 
FiGUrE 4 | T cells induced by vaccination with thrombospondin-related adhesion protein (TRAP) antigen from P. falciparum T9/96 strain are highly cross-reactive. 
Scatter plots show individual ex vivo IFNγ enzyme-linked immunospot responses to TRAP peptides from T9/96 and 3D7 strains, respectively. (a) Responses 
pre-vaccination. (B) Responses 3 weeks post-prime with ChAd63 multiple epitope string thrombospondin-related adhesion protein (ME-TRAP). (C,D) Responses  
at day 63 and day 168, 7 and 112 days post-boost with MVA ME-TRAP, respectively. Numbers indicate the percentage of positive responses for each age group  
at each time point for both parasite strains. LLD, lower limit of detection of the assay. Lines represent geometric mean.
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A population of monofunctional CD8+ T  cells, positive for 
IFNγ, but not for IL-2 or TNFα, previously found associated with 
delay to patency following controlled human malaria infection of 
malaria-naïve adult volunteers using this vaccine (9) was detected 
in all three infant groups (Figure S7 in Supplementary Material). 
Boosting with MVA expanded this response, although this 
increase in magnitude only reached significance in the 16- and 
8-week-old infants (p = 0.002 and p = 0.016, two-tailed Kruskal–
Wallis test); peak responses at day 63 did not differ significantly 
between groups. This was accompanied by a noticeable rise in the 
percentage of responders, irrespective of the age group. Positive 
responses were observed in 92.3, 85.7, and 66.7% of infants at day 
63 as compared to 33.3, 33.3, and 53.3% at day 21 in the 16-, 8-, 
and 1-week-old groups, respectively.
Anti-TRAP IgG Responses to Vaccination
Pre-vaccination IgG titers to TRAP were below the detection limit 
in all participants (Figure 7A). After vaccination with ChAd63 
ME-TRAP, titers increased significantly (p  <  0.05, Kruskal–
Wallis test) with 13% of participants becoming seropositive by 
day 21. There were no significant differences in antibody response 
between age groups at any time. Boosting with MVA ME-TRAP 
Material) and for the CD8+ T cell response of the 16- and 8-week 
olds (p = 0.001 and p = 0.027, respectively, Kruskal–Wallis test, 
Figures S5B–D in Supplementary Material). Prior to boosting, 
IFNγ was largely secreted by CD4+ T cells, except in the youngest 
age group where CD8+ T cells were the main IFNγ producers. 
By contrast, after boosting with MVA, the contribution to total 
IFNγ response to TRAP was more evenly distributed between 
both T cell populations in all age groups (Figure 5).
Thrombospondin-related adhesion protein-specific T  cells 
comprised a mixture of T cell subsets with distinct effector func-
tions in both the CD4+ and CD8+ T cell populations (Figure 6). 
Seven days after boosting with MVA, the functional profile of 
the peak CD4+ and CD8+ T cell responses was similar between 
study groups [no significant difference in the phenotype distribu-
tion using the non-parametric partial permutation test in Spice 
(NPPPTS)] (24). The majority of cytokine-secreting T  cells 
produced a single cytokine, T cell subsets expressing two or three 
cytokines simultaneously were also observed in all age groups 
(Figure S6 in Supplementary Material). As previously observed, 
CD4+ T  cells displayed a more polyfunctional phenotype than 
CD8+ T cells, across all three age groups (p = 0.05, p = 0.02, p = 0.05 
in the 16-, 8-, and 1-week-old groups, respectively, NPPPTS).
FiGUrE 5 | CD4+ and CD8+ T cell contribution to total IFNγ response to 
thrombospondin-related adhesion protein (TRAP). Pie charts display the 
proportion of IFNγ produced by CD4+ (black) and CD8+ (gray) T cells as a 
fraction of the total IFNγ response to TRAP post-prime and post-boost 
vaccination. Here, any negative response was excluded from analysis.
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increased the seropositivity rate across all groups to 93% at day 63 
and titers remained significantly above pre-vaccination levels at 
8 and 16 weeks after boosting (p < 0.0001, Kruskal–Wallis test). 
88% of participants remained seropositive at the last time point 
measured.
Titers in this trial were compared to titers measured in previ-
ous trials of this vaccine in adults and older infants, detected 
using the same ELISA assay, reagents and operator (10, 13). 
All groups received 5 × 1010 vp ChAd63, with adults receiving 
2 × 108 pfu of MVA and all other groups receiving 1 × 108 pfu 
of MVA. One week after boosting, titers in all groups were strik-
ingly and significantly higher than those in Gambian adults and 
children aged 2–6  years (Figure  7B, p <  0.01, Kruskal–Wallis 
test). Responses were significantly lower in all three groups than 
in previous studies in infants aged 5–12 months (p < 0.05) or 
10 weeks of age without EPI vaccine coadministration (p < 0.01, 
Kruskal–Wallis test), identifying these age groups as preferred 
ages for use of vectored vaccines for antibody induction. The 
substantially higher antibody immunogenicity in several young 
age groups in Africa compared to UK adults (Figure  7B) 
cautions that some phase Ia trials in adults may importantly 
underestimate the potency of vectored vaccines in infant target 
populations.
IgG Responses to EPI Vaccines
Responses to EPI vaccines, 8 weeks post-primary series, were not 
significantly different between vaccinees and controls although 
the study was not powered to detect modest significant differ-
ences (Figures 7C,D).
DiSCUSSiOn
This clinical trial evaluated the responses to ChAd63 MVA 
ME-TRAP when given simultaneously with EPI vaccines 
among healthy Gambian infants and neonates. Vaccines were 
co-administered as early as 1 week of age, as BCG and the first 
doses of hepatitis B and OPVs are administered at this time point.
Adverse events observed in the coadministration groups were 
similar to those reported in our previous studies of these vectored 
vaccines, where fever was the most frequently observed in the 
10-week-old group and all vaccine-related AEs were mild and 
resolved within 1 day after onset of symptoms (13). Not surpris-
ingly, a significantly higher proportion of infants who received 
ChAd63 MVA ME-TRAP with EPI vaccines had fever compared 
to those who received EPI vaccines alone. This finding may be 
explained by the concurrence of inflammatory processes as a 
result of multiple injections. Similarly, pain and discoloration at 
EPI injection sites were more frequently reported in participants 
who received EPI with study vaccines across all age groups while 
swelling at EPI sites were seen in participants who received EPI 
with MVA study vaccine. Nevertheless, these symptoms were of 
mild intensity and resolved within 48 h post-vaccination.
The increased frequency of fever observed following adminis-
tration of study vaccines in 1-week-old cohort was notably Grade 
1 (of mild intensity) and these resolved within 24 h without use 
of any medication. There were also no associated danger signs 
such as refusal of feeds, abnormal cry and convulsion; hence 
full septic work-up was not done. Given that low grade fever is 
not unexpected in neonates whose immune system is immature, 
observing Grade 1 fever over a short duration in this age group 
lends credence to the safety and tolerability of the study vaccines. 
However, given the small sample size of the neonates studied, 
further evaluation is required in larger sample of this cohort. 
Furthermore, the preponderance of unsolicited symptoms such 
as skin sepsis observed among study vaccine recipients in 1- and 
8-week-old cohorts was clinically investigated and found to be 
caused by poor hygienic practices by participants’ mothers. The 
participants fully recovered following improved hygiene and 
a course of antibiotics. Overall, these observations show that 
coadministration of ChAd63 MVA ME-TRAP with EPI vaccines 
is safe and well tolerated in Gambian infants and neonates.
As in previous studies, we observed induction of substantial 
and durable T cell responses maintained beyond 112 days post-
MVA, which comprised both CD4+ and CD8+ T cells capable of 
secreting multiple cytokines, with similar phenotypes to those 
seen in older infants, children, and adults (11, 13, 14). Importantly, 
these high levels of effector cellular immunity, as measured by 
ELISpot, with or without adjustment of T cells per million PMBC 
AB
FiGUrE 6 | Multifunctionality of peak CD4+ and CD8+ T cell responses to thrombospondin-related adhesion protein (TRAP) at day 63 (1 week post-boosting). Cytokine 
production from CD4+ (a) and CD8+ (B) T cells was analyzed using Boolean gating analysis. Pie charts illustrate the relative frequency of each combination of cytokines, 
indicated in the bar chart below, as a fraction of the total cytokine response. Bar charts show the absolute frequency of each subset in response to stimulation with 
TRAP peptides, compared between each age group. Bars show median responses in this case as geometric mean is not available in SPICE. Any response which was 
less than or equal to the background (unstimulated) response was replaced by lower limit of detection value in bar chart and excluded from pie charts.
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FiGUrE 7 | Antibody responses to Expanded Program on Immunization (EPI) and multiple epitope string thrombospondin-related adhesion protein (ME-TRAP) 
vaccination. (a) IgG responses to vaccination with ChAd63 ME-TRAP (day 0) and MVA ME-TRAP (day 56). Scatter plots show peak responses post-prime (day 21) 
and post-boost (day 63). Group 1—16 weeks, group 2—8 weeks, and group 3—1 week old at first vaccination. All comparisons use Kruskal–Wallis with Dunn’s 
post-test, comparing responses at day 0 with post-vaccination responses for groups 1–3 combined. No significant differences between groups were observed at 
any time point. (B) Comparison of peak IgG responses with data from previous trials (14). Responses in all groups combined from the present study were compared 
to those from a study in the same population that received the same dose and vaccine regimen in the absence of EPI coadministration. (C,D) Responses to EPI 
vaccination at 24 weeks, 8 weeks after last primary EPI, among ME-TRAP vaccinees and controls for diphtheria, tetanus, pertussis, Haemophilus influenza B, 
Hepatitis B, and polio serotypes 1–3 (C) and pneumococcal immunization (PCV 13) by serotype (D). No significant differences between groups were observed 
(*p < 0.05, **p < 0.01, ****p < 0.001).
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to T cells per milliliter of blood, are as high or higher than those 
observed in UK adult vaccinees protected against five bite malaria 
sporozoite challenge (9) and those observed in Kenyan adult vac-
cinees showing efficacy against natural infection (12).
Although responses from the 1-week olds were generally 
lower than those seen in the older infants, probably due to age-
related differences in immunity, peak responses 1 week follow-
ing boost vaccination in this age group were also significantly 
higher than those previously achieved in Gambian adults (11) as 
well as in older children in The Gambia and Burkina Faso (14) 
using the same vaccine approach, further demonstrating that 
viral vectored vaccines represent an effective mean of triggering 
cellular immunity in early life. Overall, these data further sup-
port previous findings of increase, and not decrease, in cellular 
immunogenicity in young infants, with the highest responses 
induced in the 8-week olds being almost identical to those of 
10-week olds (12,277 and 12,074  SFC/ml, respectively), who 
received the same vaccine separately from EPI vaccines (14).
As previously reported, responses to TRAP were broad, indicat-
ing the recognition of several potential epitopes within the TRAP 
antigen (9, 11). Moreover, although TRAP from T9/96 vaccine 
strain differs by 6.5% AA from 3D7 TRAP sequence (26), peak 
homologous and heterologous antigen-specific T cell responses 
were comparable and positively correlated, pointing out a high 
degree of cross-reactivity. Altogether, these observations confirm 
that this vaccine should not be substantially affected neither by 
potentially great genetic variation in HLA types in target popula-
tions nor by antigen polymorphism.
15
Mensah et al. ME-TRAP and EPI Vaccines Coadministration
Frontiers in Immunology | www.frontiersin.org November 2017 | Volume 8 | Article 1551
Flow cytometry analysis further revealed vaccine-induced 
cytokine production by both antigen-specific CD4+ and CD8+ 
T cells. Importantly, despite major differences (including differ-
ences in sensitivity or the use of PBMC vs. whole blood) between 
the two assays, peak total frequency of IFNγ-producing TRAP-
specific CD3+ T cells, assessed 1 week post-MVA by intracellular 
staining, positively correlated with peak IFNγ responses to TRAP 
measured by ELISpot, suggesting that blood volumes as little as 
1.05 ml could be sufficient to measure the vaccine response in 
young infants.
Priming vaccination elicited predominantly CD4+ T  cell 
responses, and while CD8+ T  cell responses were observed, 
these required the MVA booster vaccination to reach similar 
levels. While previous studies have reported age-specific differ-
ences in neonatal adaptive immunity with a reduction in infant 
IFNγ responses to hepatitis B (27) or oral polio (28) vaccines as 
compared to vaccinated adults, BCG, or DNA vaccinations at 
birth have been shown to elicit strong T helper type 1 and CD8+ 
T cell responses during neonatal life (29–31). Similarly, our find-
ings illustrate the induction of antigen-specific CD4+ and CD8+ 
T cells producing type 1 cytokines, highlighting potent cellular 
immunogenicity of our vaccine candidate in young infants. This 
finding confirms that newborns can develop potent cellular 
immune responses under certain circumstances, as previously 
observed in infants congenitally infected with Trypanosoma cruzi 
(32) or cytomegalovirus (33), who developed strong CD8+ T cell 
responses.
Multiparameter flow cytometric analysis revealed multiple 
cytokine-secreting T  cell subsets expressing IFNγ, IL-2, and 
TNFα in all combinations, including a phenotype previously 
identified as an immune correlate of vaccine-induced protection 
against heterologous challenge in naïve adults (9). Although these 
responses were lower in this setting as compared to those seen in 
UK and Kenyan adults (9, 12), this provides grounds for future 
studies of vaccine efficacy in pediatric populations.
This viral vector approach also induced substantial IgG anti-
body responses to TRAP in these infants and neonates, despite a 
lack of humoral immunogenicity in adults in the same population 
(11, 14). Peak titers were similarly significantly higher in this 
cohort than those seen in Gambian children aged 2- to 6-year old, 
confirming an overall higher immunogenicity in the youngest age 
groups. The addition of a humoral component of immunity elicited 
by this vaccine at the pre-erythrocytic stage could be useful, given 
that viral vectors are predominantly employed for their ability 
to induce cell-mediated immunity. With our recent observation 
that vaccine-induced TRAP antibody responses could play a role 
in reducing liver parasite burden (34), this raises the possibility 
of an improved vaccine efficacy via synergistic protection in 
young infants as compared to that observed in adults. The leading 
malaria vaccine candidate RTS,S shows reduced immunogenicity 
and associated efficacy in infants aged 6–12 weeks (17), compared 
with those aged 5–17  months. We observed the same trend in 
this study, although pre-vaccination titers to TRAP were less 
frequently observed, suggesting that pre-existing immunity to 
the vaccine antigen is not the cause in this case.
Given the advantages of integrating a new vaccine within 
the EPI schedule, including reduced clinic visits, increased 
immunization coverage, and possible enhanced immunogenicity 
of the vaccines (15), these benefits must be carefully considered 
against adverse immunological interference that may be caused 
by coadministration of T cell inducing vaccines with EPI vaccines. 
Although our findings support concomitant administration of 
ChAd63 MVA ME-TRAP with licensed EPI vaccines, these find-
ings need further evaluation in larger non-interference trials.
This study demonstrates that coadministration of ChAd63 
MVA ME-TRAP with EPI vaccines is safe and well tolerated 
and induces potent immune responses against P. falciparum 
antigens. The potency of these vectored vaccines for both T cell 
and antibody responses in early infancy suggests that vectors may 
also be useful for targeting other pathogens, such as RSV, where 
protection in the first months of life is required.
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